Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Prior participation in and the successful completion of the R727-CL-1003 study (NCT01266876).~2. Patients must be on a stable daily statin regimen for at least 3 weeks before prior to entry into the study~3. A negative urine pregnancy at the screening/baseline visit for women of childbearing potential~Key Exclusion Criteria:~1. Reported a drug-related serious adverse event (SAE) or drug-related clinical or laboratory adverse event (AE) in the R727-CL-1003 study that resulted in early termination or withdrawal~2. Significant protocol deviation in R727-CL-1003, such as non-compliance by the investigator or patient~3. Low-density lipoprotein (LDL) apheresis within 12 months before the screening/baseline visit~Note: Other exclusion criteria applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Matched to Alirocumab (Type: PLACEBO_COMPARATOR): Participants who received placebo in parent study (NCT01576484), has received a subcutaneous injection of placebo matched to alirocumab every 2 weeks for 4 years in this study.
- Alirocumab 150 mg (Type: EXPERIMENTAL): Participants who received alirocumab in parent study (NCT01576484), has received a subcutaneous injection of alirocumab 150 milligram (mg) every 2 weeks for 4 years in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).